Drug Type Universal CAR-T, Induced pluripotent stem cells (iPSC) |
Synonyms iPSC-Derived Allogeneic CD19/CD20 CAR-T cell(Notch Therapeutics) |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | Canada | 01 Dec 2024 | |
B-Cell Lymphoma | Preclinical | Canada | 01 Dec 2024 | |
Hematologic Neoplasms | Preclinical | United States | 05 Nov 2019 | |
Hematologic Neoplasms | Preclinical | Canada | 05 Nov 2019 |